New data reveals that longer-term lebrikizumab treatment significantly improves outcomes for patients with moderate-to-severe atopic dermatitis who didn’t meet response criteria by week 16.
Effective management of atopic dermatitis (AD) has been one of the top priorities for physicians over the years, as quality of life in these patients is compromised due to the disruptive symptoms that ...